

Manufacturer	NDC 11	Drug Name	Commercial L	Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally
Apotex Corp	60505628900	Eribulin Mesylate Injection 1 mg / 2ml	5/3/2024	No marketing activities were undertaken. Product launched

The estimated volume of patients who may be prescribed the drug	Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	Date and price of acquisition if the drug was not developed by the manufacturer
13	N	